Chemokine MIP-2/CXCL2, acting on CXCR2, induces motor neuron death in primary cultures

NeuroImmunoModulation

Volumn 14, Issue 6, 2007, Pages 310-316

  De Paola, Massimiliano ^a   Buanne, Pasquale ^b   Biordi, Leda ^c   Bertini, Riccardo ^b   Ghezzi, Pietro ^a   Mennini, Tiziana ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Amyotrophic lateral sclerosis; Chemokines; CXCR2; IL 8; Motor neuron culture; Reparixin

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; GLUTAMIC ACID; GLUTAMINE; INTERLEUKIN 8; KAINIC ACID; MACROPHAGE INFLAMMATORY PROTEIN 2; REPARIXIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; IMMUNE SYSTEM; IMMUNOCYTOCHEMISTRY; MOTONEURON; MOTOR NEURON DISEASE; MOUSE; NERVE CELL CULTURE; NERVE CELL NECROSIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL DEATH; CELLS, CULTURED; CHEMOKINE CXCL2; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; MOTOR NEURONS; NERVE DEGENERATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, INTERLEUKIN-8B; SULFONAMIDES;

EID: 44349130492     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000123834     Document Type: Article

References (32)

1. Lee JR, Annegers JF, Appel SH: Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci 1995;132:207-215.
2. Millul A, Beghi E, Logroscino G, Micheli A, Vitelli E, Zardi A: Survival of patients with amyotrophic lateral sclerosis in a population-based registry. Neuroepidemiology 2005;25:114-119.
3. Preux PM, Couratier P, Boutros-Toni F, Salle JY, Tabaraud F, Bernet-Bernady P, Vallat JM, Dumas M: Survival prediction in sporadic amyotrophic lateral sclerosis. Age and clinical form at onset are independent risk factors. Neuroepidemiology 1996;15:153-160.
4. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM: Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study. Arch Neurol 2000;57:1171-1176.
5. Barbeito LH, Pehar M, Cassina P, Vargas MR, Peluffo H, Viera L, Estevez AG, Beckman JS: A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Res Brain Res Rev 2004;47:263-274.
6. Rao SD, Weiss JH: Excitotoxic and oxidative cross-talk between motor neurons and glia in ALS pathogenesis. Trends Neurosci 2004;27:17-23.
7. Sargsyan SA, Monk PN, Shaw PJ: Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia 2005;51:241-253.
8. Baron P, Bussini S, Cardin V, Corbo M, Conti G, Galimberti D, Scarpini E, Bresolin N, Wharton SB, Shaw PJ, Silani V: Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis. Muscle Nerve 2005;32:541-544.
9. Ford L, Rowe D: Interleukin-12 and interferon-gamma are not detectable in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:118-120.
10. Gallo P, Sivieri S, Rinaldi L, Yan XB, Lolli F, De Rossi A, Tavolato B: Intrathecal synthesis of interleukin-10 (IL-10) in viral and inflammatory diseases of the central nervous system. J Neurol Sci 1994;126:49-53.
11. Joerg Stuerenburg H, Jung R, Schoser BG: Age effects on interleukin-6 and interleukin-1beta responses to endurance exercise in patients with neuromuscular diseases. Arch Gerontol Geriatr 1999;29:21-27.
12. Krieger C, Perry TL, Ziltener HJ: Amyotrophic lateral sclerosis: interleukin-6 levels in cerebrospinal fluid. Can J Neurol Sci 1992;19:357-359.
13. Moreau C, Devos D, Brunaud-Danel V, Defebvre L, Perez T, Destee A, Tonnel AB, Lassalle P, Just N: Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? Neurology 2005;65:1958-1960.
14. Poloni M, Facchetti D, Mai R, Micheli A, Agnoletti L, Francolini G, Mora G, Camana C, Mazzini L, Bachetti T: Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci Lett 2000;287:211-214.
15. Sekizawa T, Openshaw H, Ohbo K, Sugamura K, Itoyama Y, Niland JC: Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci 1998;154:194-199.
16. Wilms H, Rosenstiel P, Sievers J, Deuschl G, Lucius R: Cerebrospinal fluid from patients with neurodegenerative and neuroinflammatory diseases: no evidence for rat glial activation in vitro. Neurosci Lett 2001;314:107-110.
17. Cartier L, Hartley O, Dubois-Dauphin M, Krause KH: Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. Brain Res Brain Res Rev 2005;48:16-42.
18. Xia M, Hyman BT: GROalpha/KC, a chemokine receptor CXCR2 ligand, can be a potent trigger for neuronal ERK1/2 and PI-3 kinase pathways and for tau hyperphosphorylation - a role in Alzheimer's disease? J Neuroimmunol 2002;122:55-64.
19. Horuk R, Martin AW, Wang Z, Schweitzer L, Gerassimides A, Guo H, Lu Z, Hesselgesser J, Perez HD, Kim J, Parker J, Hadley TJ, Peiper SC: Expression of chemokine receptors by subsets of neurons in the central nervous system. J Immunol 1997;158:2882-2890.
20. Omari KM, John G, Lango R, Raine CS: Role for CXCR2 and CXCL1 on glia in multiple sclerosis. Glia 2006;53:24-31.
21. Omari KM, John GR, Sealfon SC, Raine CS: CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain 2005;128:1003-1015.
22. Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G, Cervellera MN, Di Cioccio V, Cesta MC, Galliera E, Martinez FO, Di Bitondo R, Troiani G, Sabbatini V, D'Anniballe G, Anacardio R, Cutrin JC, Cavalieri B, Mainiero F, Strippoli R, Villa P, Di Girolamo M, Martin F, Gentile M, Santoni A, Corda D, Poli G, Mantovani A, Ghezzi P, Colotta F: Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci USA 2004;101:11791-11796.
23. Comoletti D, Muzio V, Capobianco A, Ravizza T, Mennini T: Nitric oxide produced by non-motoneuron cells enhances rat embryonic motoneuron sensitivity to excitotoxins: comparison in mixed neuron/glia or purified cultures. J Neurol Sci 2001;192:61-69.
24. Araujo DM, Cotman CW: Trophic effects of interleukin-4, -7 and -8 on hippocampal neuronal cultures: potential involvement of glial-derived factors. Brain Res 1993;600:49-55.
25. Bruno V, Copani A, Besong G, Scoto G, Nicoletti F: Neuroprotective activity of chemokines against N-methyl- D -aspartate or beta-amyloid-induced toxicity in culture. Eur J Pharmacol 2000;399:117-121.
26. Limatola C, Ciotti MT, Mercanti D, Santoni A, Eusebi F: Signaling pathways activated by chemokine receptor CXCR2 and AMPAtype glutamate receptors and involvement in granule cells survival. J Neuroimmunol 2002;123:9-17.
27. Limatola C, Ciotti MT, Mercanti D, Vacca F, Ragozzino D, Giovannelli A, Santoni A, Eusebi F, Miledi R: The chemokine growth-related gene product beta protects rat cerebellar granule cells from apoptotic cell death through alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors. Proc Natl Acad Sci USA 2000;97:6197-6201.
28. Thirumangalakudi L, Yin L, Rao HV, Grammas P: IL-8 induces expression of matrix metalloproteinases, cell cycle and pro-apoptotic proteins, and cell death in cultured neurons. J Alzheimers Dis 2007;11:305-311.
29. Kalehua AN, Nagel JE, Whelchel LM, Gides JJ, Pyle RS, Smith RJ, Kusiak JW, Taub DD: Monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 are involved in both excitotoxin-induced neurodegeneration and regeneration. Exp Cell Res 2004;297:197-211.
30. Garau A, Bertini R, Colotta F, Casilli F, Bigini P, Cagnotto A, Mennini T, Ghezzi P, Villa P: Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia. Cytokine 2005;30:125-131.
31. Villa P, Triulzi S, Cavalieri B, Di Bitondo R, Bertini R, Barbera S, Bigini P, Mennini T, Gelosa P, Tremoli E, Sironi L, Ghezzi P: The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats. Mol Med 2007;13:125-133.
32. Gorio A, Madaschi L, Zadra G, Marfia G, Cavalieri B, Bertini R, Di Giulio AM: Reparixin, an inhibitor of CXCR2 function, attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord. J Pharmacol Exp Ther 2007;322:973-981.